Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.51 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29855673 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL30686144 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL30422046 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL119506 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL3724266 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL25211293 | 0.92 | MDM4 (0.52) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL25268165 | 0.92 | MDM4 (0.52) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL30834626 | 0.92 | MDM4 (0.52) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL28312907 | 0.91 | MDM4 (0.47) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29221396 | 0.91 | MDM4 (0.50) | MDM4TP53CASP3MDM2SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117279933-A | Cyclic compounds having selective KRAS inhibition relative to HRAS and NRAS | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| EP-3515880-B1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF ENCODED LIBRARIES | HITGEN INC (CN) | 2023-05-10 | — | — | EP | disclosed |
| WO-2022234853-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| CN-114729006-A | Cyclic peptide compounds having Kras inhibitory activity | 中外制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| EP-2970390-B1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2019-11-06 | — | — | EP | disclosed |
| CN-110156807-A | The purposes of aspergillus flavus OUCMDZ-2205 secondary metabolite | 嘉兴市爵拓科技有限公司 | 2019-08-23 | — | — | CN | disclosed |
| US-9879046-B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-30 | — | — | US | disclosed |
| US-20140294898-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY | 2014-10-02 | — | — | US | disclosed |
| WO-2014151634-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-6372883-B1 | FOR THERAPY AND PROPHYLAXIS OF INFECTIONS CAUSED BY HEPATITIS C, HEPATITIS G AND HUMAN GB VIRUSES | HOFFMANN-LA ROCHE INC. | 2002-04-16 | — | — | US | disclosed |
| US-6187905-B1 | PEPTIDE COMPOUND WHICH INHIBITS VIRAL PROTEINASES; VIRICIDES FOR HEPATITIS C, HEPATITIS G, AND HUMAN GB VIRUSES | HOFFMANN-LA ROCHE INC. | 2001-02-13 | — | — | US | disclosed |
| US-6018020-A | VIRICIDES WHICH ARE PROTEASE INHIBITORS AGAINST HEPATITIS C AND HEPATITIS G | HOFFMAN-LA ROCHE INC. (US) | 2000-01-25 | — | — | US | disclosed |
| EP-0941233-A2 | ANTIVIRAL PEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-15 | — | — | EP | disclosed |
| US-5866684-A | Peptidyl inhibitors of viral proteases | HOFFMANN-LA ROCHE INC. (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998022496-A2 | ANTIVIRAL PEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885CASP3 3906/4885 |
| US-20140294898-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | CD274, PDCD1, PDCD1LG2 | MDM4 550/4885TP53 100/4885CASP3 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.